New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist

The American Journal of Cardiology
H Koike

Abstract

CS-866 is a new angiotensin II receptor blocker that has demonstrated effectiveness for lowering blood pressure in animal models of hypertension. Given the proposed involvement of the renin-angiotensin system in diabetic nephropathy and atherosclerosis, we have tested CS-866 in animal models of these conditions. The renal protective properties of CS-866 were examined in the Zucker diabetic fatty (ZDF) rat, a model of type 2 diabetes that develops progressive hyperglycemia, glomerulosclerosis, and proteinuria. Treatment of ZDF rats with CS-866 in the diet for 19 weeks resulted in a dose-dependent reduction in urinary protein excretion compared with vehicle-treated control rats, which was independent of changes in blood pressure and glycemic state. The antiatherosclerotic properties of CS-866 were tested in 2 animal models. In the first study, cynomolgus monkeys were fed a high-cholesterol diet for 6 months while receiving CS-866 or vehicle. At the end of this period, CS-866-treated animals had 64% less plaque area in the aorta than controls. CS-866 was also tested in the Watanabe heritable hyperlipidemic (WHHL) rabbit model of atherosclerosis. WHHL rabbits were treated for 32 weeks with CS-866 (1 mg/kg), pravastatin (50 mg/kg), ...Continue Reading

References

Apr 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·T KitaJ L Goldstein
Oct 16, 1995·European Journal of Pharmacology·M MizunoH Koike
Jun 20, 1996·The New England Journal of Medicine·T L GoodfriendK J Catt
Jan 1, 1996·Journal of the American Society of Nephrology : JASN·J P VoraS Anderson
Sep 21, 2000·Kidney International. Supplement·D J LeeheyR Singh

❮ Previous
Next ❯

Citations

Feb 28, 2007·Vascular Health and Risk Management·Hans R Brunner
Sep 23, 2010·Vascular Health and Risk Management·Carlos M Ferrario, Ronald D Smith
May 5, 2011·Journal of Biomedicine & Biotechnology·Tsutomu KobayashiMasashi Shiomi
Jul 1, 2008·Future Cardiology·Christoph Schindler, Carlos M Ferrario
Jun 9, 2004·Life Sciences·Minoru SasakiHiroyoshi Matsumoto
Apr 21, 2005·European Journal of Pharmacology·Hiroaki NakamuraTomihisa Yokoyama
Mar 12, 2004·Expert Opinion on Pharmacotherapy·Steven G Chrysant, George S Chrysant
Oct 7, 2004·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Toshio Sada, Makoto Mizuno
Nov 7, 2007·Journal of Hypertension·José W A van der HoornJ Wouter Jukema
Feb 6, 2003·Journal of Hypertension·Ulf de Faire
Oct 3, 2002·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Haruhiro TokoIssei Komuro
Oct 18, 2002·American Journal of Hypertension·Ernesto L Schiffrin, UNKNOWN Canadian Institutes of Health Research Multidisciplinary Research Group on Hypertension
Dec 31, 2003·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Paul S Jellinger, UNKNOWN FACE
Mar 17, 2004·The Journal of Toxicological Sciences·Seiya OgataSunao Manabe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.